Recent studies have highlighted the potential of ROCK2 inhibition as a promising therapeutic approach for immune-associated diseases such as systemic lupus erythematosus (SLE), IBD, and chronic GVHD [45,46,47]. Here, ROCK2 is linked to inflammatory bowel disease.